Literature DB >> 8908700

The T-body approach: potential for cancer immunotherapy.

Z Eshhar1, N Bach, C J Fitzer-Attas, G Gross, J Lustgarten, T Waks, D G Schindler.   

Abstract

Entities:  

Mesh：

Year:  1996        PMID： 8908700     DOI： 10.1007/bf00820666

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN： 0344-4325


× No keyword cloud information.
  29 in total

1.  Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity.

Authors:  G Gross; G Gorochov; T Waks; Z Eshhar
Journal:  Transplant Proc       Date:  1989-02       Impact factor: 1.066

2.  Functional expression in mast cells of chimeric receptors with antibody specificity.

Authors:  N L Bach; T Waks; D G Schindler; Z Eshhar
Journal:  Cell Biophys       Date:  1994

Review 3.  Making antibodies by phage display technology.

Authors:  G Winter; A D Griffiths; R E Hawkins; H R Hoogenboom
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

Review 4.  Barriers to drug delivery in solid tumors.

Authors:  R K Jain
Journal:  Sci Am       Date:  1994-07       Impact factor: 2.142

5.  Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli.

Authors:  J S Huston; D Levinson; M Mudgett-Hunter; M S Tai; J Novotný; M N Margolies; R J Ridge; R E Bruccoleri; E Haber; R Crea
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

6.  Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.

Authors:  G Gross; T Waks; Z Eshhar
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

7.  A spacer region between the single chain antibody- and the CD3 zeta-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity.

Authors:  D Moritz; B Groner
Journal:  Gene Ther       Date:  1995-10       Impact factor: 5.250

8.  Specific elimination of IgE production using T cell lines expressing chimeric T cell receptor genes.

Authors:  J Lustgarten; Z Eshhar
Journal:  Eur J Immunol       Date:  1995-10       Impact factor: 5.532

9.  Chimeric zeta-receptors direct human natural killer (NK) effector function to permit killing of NK-resistant tumor cells and HIV-infected T lymphocytes.

Authors:  A C Tran; D Zhang; R Byrn; M R Roberts
Journal:  J Immunol       Date:  1995-07-15       Impact factor: 5.422

Review 10.  Monoclonal antibodies in cancer therapy.

Authors:  G Riethmüller; E Schneider-Gädicke; J P Johnson
Journal:  Curr Opin Immunol       Date:  1993-10       Impact factor: 7.486
View more
  25 in total

Review 1.  Generation of recombinant antibodies.

Authors:  S M Kipriyanov; M Little
Journal:  Mol Biotechnol       Date:  1999-09       Impact factor: 2.695

2.  Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen.

Authors:  M C Gong; J B Latouche; A Krause; W D Heston; N H Bander; M Sadelain
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

Review 3.  Using gene therapy to manipulate the immune system in the fight against B-cell leukemias.

Authors:  Diana C G Bouhassira; Joshua J Thompson; Marco L Davila
Journal:  Expert Opin Biol Ther       Date:  2015-02-09       Impact factor: 4.388

4.  T cell avidity and tumor immunity: problems and solutions.

Authors:  Arthur A Hurwitz; Steven M Cuss; Katherine E Stagliano; Ziqiang Zhu
Journal:  Cancer Microenviron       Date:  2013-12-20

Review 5.  Recent advances and discoveries in the mechanisms and functions of CAR T cells.

Authors:  Rebecca C Larson; Marcela V Maus
Journal:  Nat Rev Cancer       Date:  2021-01-22       Impact factor: 60.716

6.  Myeloid Conditioning with c-kit-Targeted CAR-T Cells Enables Donor Stem Cell Engraftment.

Authors:  Yasuyuki Arai; Uimook Choi; Cristina I Corsino; Sherry M Koontz; Masaki Tajima; Colin L Sweeney; Mary A Black; Steven A Feldman; Mary C Dinauer; Harry L Malech
Journal:  Mol Ther       Date:  2018-03-10       Impact factor: 11.454

7.  Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma.

Authors:  Andrea Schmidts; Maria Ormhøj; Bryan D Choi; Allison O Taylor; Amanda A Bouffard; Irene Scarfò; Rebecca C Larson; Matthew J Frigault; Kathleen Gallagher; Ana P Castano; Lauren S Riley; Maria L Cabral; Angela C Boroughs; Rubí M-H Velasco Cárdenas; Wolfgang Schamel; Jing Zhou; Sean Mackay; Yu-Tzu Tai; Kenneth C Anderson; Marcela V Maus
Journal:  Blood Adv       Date:  2019-11-12

Review 8.  Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.

Authors:  Marc Cartellieri; Michael Bachmann; Anja Feldmann; Claudia Bippes; Slava Stamova; Rebekka Wehner; Achim Temme; Marc Schmitz
Journal:  J Biomed Biotechnol       Date:  2010-05-05

Review 9.  CAR therapy: the CD19 paradigm.

Authors:  Michel Sadelain
Journal:  J Clin Invest       Date:  2015-09-01       Impact factor: 14.808

Review 10.  Novel delivery methods to achieve immunomodulation.

Authors:  David J Gould; Yuti Chernajovsky
Journal:  Curr Opin Pharmacol       Date:  2007-07-03       Impact factor: 5.547
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.